Department of Experimental Oncology, IRCCS European Institute of Oncology, Milano, Italy.
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
J Exp Med. 2020 Aug 3;217(8). doi: 10.1084/jem.20191920.
CD8+ T cells are master effectors of antitumor immunity, and their presence at tumor sites correlates with favorable outcomes. However, metabolic constraints imposed by the tumor microenvironment (TME) can dampen their ability to control tumor progression. We describe lipid accumulation in the TME areas of pancreatic ductal adenocarcinoma (PDA) populated by CD8+ T cells infiltrating both murine and human tumors. In this lipid-rich but otherwise nutrient-poor TME, access to using lipid metabolism becomes particularly valuable for sustaining cell functions. Here, we found that intrapancreatic CD8+ T cells progressively accumulate specific long-chain fatty acids (LCFAs), which, rather than provide a fuel source, impair their mitochondrial function and trigger major transcriptional reprogramming of pathways involved in lipid metabolism, with the subsequent reduction of fatty acid catabolism. In particular, intrapancreatic CD8+ T cells specifically exhibit down-regulation of the very-long-chain acyl-CoA dehydrogenase (VLCAD) enzyme, which exacerbates accumulation of LCFAs and very-long-chain fatty acids (VLCFAs) that mediate lipotoxicity. Metabolic reprogramming of tumor-specific T cells through enforced expression of ACADVL enabled enhanced intratumoral T cell survival and persistence in an engineered mouse model of PDA, overcoming one of the major hurdles to immunotherapy for PDA.
CD8+ T 细胞是抗肿瘤免疫的主要效应细胞,其在肿瘤部位的存在与良好的预后相关。然而,肿瘤微环境(TME)施加的代谢限制会削弱它们控制肿瘤进展的能力。我们描述了在胰腺导管腺癌(PDA)的 TME 区域中,浸润的 CD8+ T 细胞中脂质的积累,这些肿瘤既有小鼠的也有人的。在这个富含脂质但其他营养物质匮乏的 TME 中,利用脂质代谢来维持细胞功能变得尤为重要。在这里,我们发现胰腺内的 CD8+ T 细胞逐渐积累特定的长链脂肪酸(LCFAs),这些脂肪酸不仅不能提供燃料来源,还会损害它们的线粒体功能,并引发参与脂质代谢的途径的主要转录重编程,随后减少脂肪酸的分解代谢。特别是,胰腺内的 CD8+ T 细胞特异性地下调非常长链酰基辅酶 A 脱氢酶(VLCAD)酶,这加剧了 LCFAs 和非常长链脂肪酸(VLCFAs)的积累,介导脂肪毒性。通过强制表达 ACADVL 对肿瘤特异性 T 细胞进行代谢重编程,使工程化小鼠模型中的肿瘤内 T 细胞存活和持续存在得到增强,克服了胰腺导管腺癌免疫治疗的主要障碍之一。